Oakland-based New Energy Nexus joins Argonne-led public-private alliance to build lithium battery supply chain
As widespread electrification drives demand for lithium-based batteries, the battery supply chain in the United States must expand. To achieve this goal, battery manufacturers must expand their output by 20 to 30 times and establish a secure and sustainable supply chain. The U.S. Department of Energy’s (DOE) Argonne National Laboratory announced the creation of Li-Bridge, a public-private alliance committed to building this supply chain.
In the first collaboration of its kind in the U.S. battery industry, New Energy Nexus in Oakland joined two other trade associations ― NAATBatt International and New York Battery and Energy Storage Technology Consortium, Albany ― to represent more than 600 industry stakeholders to improve the supply chain. Argonne serves as the facilitator between private industry and the Federal Consortium for Advanced Batteries, which recently released a “national blueprint” for lithium batteries to the year 2030. The plan puts the United States on a path to long-term competitiveness in the global battery value chain, outlining five critical goals for generating equitable, clean-energy jobs while mitigating climate change.
Argonne will work with DOE national laboratories across the country to meet national goals. The new alliance is seen as a major step forward in developing and sustaining the battery supply chain — critical to building electric vehicles and maintaining competitiveness worldwide.
Cerebras and Argonne collaboration leads to fastest AI system
The world’s fastest AI computer, Cerebras CS-1, is the result of a collaboration between Argonne and Cerebras Systems in Los Altos, which focuses on accelerating artificial intelligence compute. Argonne was the first national laboratory to deploy the system in 2019 to solve deep learning computational and science problems. Deep learning, a subset of AI, allows computer networks to learn from large amounts of unstructured data.
The CS-1 integrates the Wafer Scale Engine, the fastest AI processor ever built, and enables AI practitioners to answer more questions and explore more ideas in less time. The CS-1 delivers record-breaking performance and scale to AI compute, and its deployment across national laboratories enables the largest supercomputer sites in the world to achieve a hundredfold to a thousandfold improvement over existing AI accelerators.
Argonne-led energy storage consortium technology leads to Sepion startup
Sepion Technologies in Emeryville was launched using technology developed at the Joint Center for Energy Storage Research (JCESR), one of DOE’s Energy Innovation Hubs. Led by Argonne, JCESR is a partnership of national laboratories, universities and industrial firms with more than 150 researchers. Its mission is to create materials that can be mixed and matched to build a diversity of next-generation batteries to transform transportation and the electric grid the way lithium-ion batteries transformed consumer electronics. JCESR developed a polymer membrane as a component of a novel design for the cells that make up a battery. That membrane gave birth to Sepion.
Since then, Sepion has been commercializing a membrane platform with a suite of products that enhance the performance and economics of lithium batteries and flow batteries. At the heart of the technology are membranes that can be dropped in with existing manufacturing processes to minimize barriers to market entry, the company website said.
Argonne teams with California firms on new drug for melanoma patients
Researchers from drug discovery company Plexxikon Inc. in Berkeley and biotechnology company Genentech in San Francisco collaborated with Argonne to develop Zelboraf®, which is sold in nearly 50 countries.
While using Argonne’s Advanced Photon Source, researchers determined the structure of a cancer‑causing mutated protein. They searched through hundreds of molecules to determine the structure of the one that could halt the cancer’s spread. The researchers wanted to develop a drug to prevent the enzyme from multiplying. The molecule the scientists selected to use in the drug functions like a lock-and-key mechanism, binding tightly to the mutated protein and blocking signals from it that tell cancer cells to multiply. The U.S. Food and Drug Administration approved Zelboraf® in 2011.